Research programme: dual E-selectin inhibitors/CXCR4 receptor antagonists - GlycoMimetics

Drug Profile

Research programme: dual E-selectin inhibitors/CXCR4 receptor antagonists - GlycoMimetics

Alternative Names: Anti-Leukemia Drug – GlycoMimetics; GMI-1257

Latest Information Update: 30 Apr 2015

Price : $50

At a glance

  • Originator GlycoMimetics
  • Class Small molecules
  • Mechanism of Action CXCR4 receptor antagonists; E-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 19 Mar 2015 Preclinical trials in Solid tumours in USA (PO)
  • 19 Mar 2015 Preclinical development is ongoing in USA
  • 13 Dec 2011 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia presented at the 53rd Annual Meeting and Exposition of the American Society of Haematology (ASH-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top